Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1224-1227

  Nozza, Silvia ^a   Canducci, Filippo ^b   Galli, Laura ^a   Cozzi Lepri, Alessandro ^c,d,e   Capobianchi, Maria Rosaria ^f   Ceresola, Elisa Rita ^b   Narciso, Pasquale ^f   Libertone, Raffaella ^f   Castelli, Paula ^g   Moioli, Mariacristina ^h   D'arminio Monforte, Antonella ^e   Castagna, Antonella ^a,e  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF MINNESOTA   (United States)

^e ICONA Foundation   (Italy)

^f NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^g Division of Infection Diseases   (Italy)

^h OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

CD4 decline; HIV 1 infection progression; Non R5 viral tropism

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RNA;

ADULT; AGING; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GENO2PHENO TEST; GENOTYPING TECHNIQUE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; SEXUALLY TRANSMITTED DISEASE; VIRAL TROPISM;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RECEPTORS, HIV; RNA, VIRAL; VIRAL LOAD; VIRAL TROPISM;

EID: 84859593970     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr600     Document Type: Article

References (11)

1. Moyle GJ, Wildfire A, Mandalia S et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191: 866-72.
2. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
3. Frange P, Galimand J, Goujard C et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009; 64: 135-41.
4. Sanchez V, Masia M, Rodeblano C et al. Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay. J Clin Microbiol 2010; 48: 4135-9.
5. McGovern RA, Thielen A, Mo T et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24: 2517-25.
6. Goetz MB, Leduc R, Kostman JR et al. Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr 2009; 50: 259-66.
7. Vandekerckhove L, Wensing A, Kaiser R et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011; 11: 394-407.
8. Anastos K, Gange SJ, Lau B et al. Association of race and gender with HIV-1 RNA levels and immunological progression. J Acquir Immune Defic Syndr 2000; 24: 218-26.
9. Swenson LC, Mo T, Dong WW et al. Deep sequencing to infer HIV-1 co-receptor usage: application of three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011; 203: 237-45.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. January 10, 2011; 1-166. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (10 November 2011, date last accessed).
11. 3). http://insight.ccbr.umn.edu/start/ (10 November 2011, date last accessed).